These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 7532758

  • 1. Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats.
    Inagaki O, Sudoh K, Shibasaki M, Nakagawa C, Honda K.
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):794-802. PubMed ID: 7532758
    [Abstract] [Full Text] [Related]

  • 2. Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats.
    Honda K, Takenaka T, Shiono K, Miyata-Osawa A, Nakagawa C.
    Jpn J Pharmacol; 1985 May; 38(1):31-41. PubMed ID: 2862302
    [Abstract] [Full Text] [Related]

  • 3. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
    Nichols AJ, Gellai M, Ruffolo RR.
    Fundam Clin Pharmacol; 1991 May; 5(1):25-38. PubMed ID: 1712335
    [Abstract] [Full Text] [Related]

  • 4. [Antihypertensive effect of arotinolol (S-596), a new adrenergic beta blocking agent, on experimental hypertension].
    Hara Y, Nakahara H, Miyagishi A, Nakatani H.
    Nihon Yakurigaku Zasshi; 1983 Aug; 82(2):103-16. PubMed ID: 6198264
    [Abstract] [Full Text] [Related]

  • 5. Adrenoceptor blocking and cardiovascular effects of the optical isomers of amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent, and the corresponding desoxy derivative (YM-11133) in rats.
    Honda K, Nakagawa C, Inagaki O, Shibasaki M, Takenaka T, Takeda M.
    Jpn J Pharmacol; 1986 Aug; 41(4):459-66. PubMed ID: 2877109
    [Abstract] [Full Text] [Related]

  • 6. Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function.
    Antonaccio MJ, High J, DeForrest JM, Sybertz E.
    J Pharmacol Exp Ther; 1986 Jul; 238(1):378-87. PubMed ID: 2873238
    [Abstract] [Full Text] [Related]

  • 7. Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxy derivative (YM-11133).
    Honda K, Takenaka T, Miyata-Osawa A, Terai M.
    J Pharmacol Exp Ther; 1986 Mar; 236(3):776-83. PubMed ID: 2869143
    [Abstract] [Full Text] [Related]

  • 8. [Antihypertensive effect of naftopidil (KT-611), a novel alpha 1-adrenoceptor antagonist, in freely moving experimental hypertensive rats and dogs].
    Kawasaki H, Nakamura S, Takasaki K, Iwamoto T, Ohjimi H, Kushiku K, Furukawa T.
    Nihon Yakurigaku Zasshi; 1990 Sep; 96(3):129-39. PubMed ID: 1980256
    [Abstract] [Full Text] [Related]

  • 9. The relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats.
    Drew GM, Hilditch A, Levy GP.
    Clin Exp Hypertens (1978); 1979 Sep; 1(5):597-611. PubMed ID: 42517
    [Abstract] [Full Text] [Related]

  • 10. Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
    Monopoli A, Bamonte F, Forlani A, Ongini E, Parravicini L.
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):256-63. PubMed ID: 6151824
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the antihypertensive activity of SK&F 86466, a selective alpha-2 antagonist, in the rat.
    Roesler JM, McCafferty JP, DeMarinis RM, Matthews WD, Hieble JP.
    J Pharmacol Exp Ther; 1986 Jan; 236(1):1-7. PubMed ID: 2867209
    [Abstract] [Full Text] [Related]

  • 12. [Antihypertensive effect of betaxolol, a cardioselective beta-adrenoceptor antagonist, in experimental hypertensive rats].
    Bessho H, Suzuki J, Narimatsu A, Tobe A.
    Nihon Yakurigaku Zasshi; 1990 Jun; 95(6):347-54. PubMed ID: 1974238
    [Abstract] [Full Text] [Related]

  • 13. Anti-hypertension effect of vanylidilol: a phenylaldehyde alpha/beta-adrenoceptor blocker with endothelium-dependent and K+ channels opening-associated vasorelaxant activities.
    Chiu CC, Wu JR, Lee CH, Liou SF, Dai ZK, Chen IJ, Yeh JL.
    Pharmacology; 2004 Mar; 70(3):140-51. PubMed ID: 14752234
    [Abstract] [Full Text] [Related]

  • 14. Hypotensive effects of YM430, a 1,4-dihydropyridine derivative, in spontaneously hypertensive rats and renal hypertensive dogs.
    Shibasaki K, Takizawa K, Uchida W, Takenaka T.
    Jpn J Pharmacol; 1997 Feb; 73(2):113-24. PubMed ID: 9074945
    [Abstract] [Full Text] [Related]

  • 15. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.
    van Zwieten PA.
    Drugs; 1993 Apr; 45(4):509-17. PubMed ID: 7684671
    [Abstract] [Full Text] [Related]

  • 16. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN.
    Drugs; 1984 Apr; 28 Suppl 2():51-68. PubMed ID: 6151891
    [Abstract] [Full Text] [Related]

  • 17. [Antihypertensive effects of a novel calcium antagonist, AE0047, in various hypertensive models].
    Kido H, Nishikawa M, Hayashi K, Kubo Y, Ohtaki Y, Fujino Y, Egi Y, Ebisu H, Inoue S, Yamanaga K, Uchida T, Nakamura N.
    Nihon Yakurigaku Zasshi; 1997 Jun; 109(6):279-89. PubMed ID: 9253775
    [Abstract] [Full Text] [Related]

  • 18. [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)].
    Nakagawa Y, Takeda K, Sakurai H, Mitomi A, Imai S.
    Nihon Yakurigaku Zasshi; 1981 Apr; 77(4):435-45. PubMed ID: 7286847
    [Abstract] [Full Text] [Related]

  • 19. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT, Levy GP.
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [Abstract] [Full Text] [Related]

  • 20. Vasoactive and beta-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent.
    Uchida Y, Nakamura M, Shimizu S, Shirasawa Y, Fujii M.
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):132-49. PubMed ID: 6135395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.